
Novo Nordisk

Novo Nordisk.. The UAE—A Natural Choice for Highly Innovative Medicines
In a move signaling an accelerated expansion strategy that transcends traditional markets, Maziar Mike Doustdar, an executive at the Danish giant Novo Nordisk, announced the company’s entry into the UAE market with the oral version of the drug "Wegovy." He described the move as a "natural choice"—a meeting point where one of the world’s most innovative medicines meets one of its most innovative nations.
His remarks, made during an interview on the Sky News Arabia program "Business with Lubna," painted a comprehensive picture of a pivotal moment in the history of treating obesity and its associated conditions. The discussion went beyond mere weight management to raise fundamental questions about the future of healthcare for more than two billion people worldwide.
The UAE: A Natural Choice for Highly Innovative Medicines
Doustdar made no secret of the fact that the decision to choose the UAE followed careful deliberation; he emphasized that the company viewed the country as an obvious choice for launching one of the world’s most innovative medicines. He noted that anyone visiting the UAE returns amazed by the progress achieved over the past few decades, highlighting the country's leading position in healthcare compared to many other nations.
Doustdar explained that the expansion into the UAE followed the US launch in record time, coinciding with rollouts in Europe and the announcement of the UK as the next market in the expansion plan. He affirmed that the company’s strategy prioritizes innovation first, followed by ensuring access to these innovations through expansion into diverse markets, thereby guaranteeing that the medicines reach the people who need them—following consultation with their physicians. From Injection to Pill: Betting on the Harder Path
At the heart of these announcements lies a remarkable story of technical innovation: how Novo Nordisk succeeded in transforming the "Wegovy" peptide—whose molecular nature previously necessitated administration via injection—into a daily oral pill. Dostdar explained that competitors chose the "easier path" by utilizing small molecules in their attempts to develop obesity pills, whereas Novo Nordisk insisted on the "harder path"—encapsulating the peptide itself within a pill.
The objective extends beyond mere competitive advantage; from the day of its launch, the new pill carries a safety profile backed by data equivalent to 50 million patient-years—a massive reservoir of reassurance that a completely new molecule cannot match. Furthermore, since the medication is essentially "Wegovy" in tablet form, the efficacy and safety established through the injectable version carry over entirely to the pill, eliminating the need to build a clinical track record from scratch.
Novo Nordisk: "Wegovy" Marks a New Step in Simplifying Obesity Treatment
The social dimension of this choice is also significant: Dostdar highlighted a large segment of the population that either views injections as taboo for cultural or religious reasons or suffers from needle phobia. This makes the "Wegovy" pill an inclusive option rather than just a convenient alternative. More Than Just Weight Loss: A Unique Competitive Edge
Dostdar emphasized that Wegovy is not a weight-loss drug in the traditional sense; rather, it remains the only GLP-1 medication with labeling that documents benefits for the heart, kidneys, and liver, alongside a reduction in stroke risk. This distinction is not merely a marketing point; in practical terms, it provides physicians with a broader clinical justification to prescribe the drug to a much wider patient demographic than just those seeking weight loss alone.
Regarding the primary concern surrounding obesity drugs—the loss of muscle mass—Dostdar acknowledged, with a candor rare for a CEO, that current achievements are "not enough." He noted that company data shows their new molecule preserves muscle mass better than competitors' products, yet there is still a long way to go toward ideally maintaining body composition throughout the weight-loss journey.
The Innovation Pipeline: Obesity Is Not a Single Disease
Dostdar described a company that refuses to view obesity as a single, uniform medical condition, asserting that "more than a billion people suffer from obesity, and it is not one disease but a diverse range of distinct conditions." This framing directly informs the company's strategy of developing multiple solutions rather than a single, all-encompassing drug.
A standout development in this regard is the "Afroxifermin" drug project, designed to treat advanced fatty liver disease. Dostdar describes it as a potential—pending data validation and regulatory approval—sole alternative to liver transplantation for a patient group that currently has no other treatment options. The product is currently in the early stages of development, awaiting the completion of Phase III trials, yet the company emphasizes that it is "moving faster than ever before."
The company’s pipeline extends beyond this; its therapeutic strategy encompasses cardiovascular, metabolic, vascular, and hematological diseases—all of which fall within the broad spectrum of conditions linked to obesity and diabetes.
**Thirty Years of Leadership and an Unstoppable Innovation Engine**
Dostdar noted that Novo Nordisk is no newcomer to the obesity landscape; the company launched the first safe anti-obesity medication in 2015 and pioneered the era of GLP-1 and peptides, a journey of research that began some thirty years ago. He personally joined the company thirty-four years ago, driven by the dream of curing diabetes rather than merely managing it—a dream that remains unfulfilled but undimmed.
Regarding the prospect of a curative treatment, Dostdar was candid about the limitations: "A curative treatment is not part of our near-term plans." However, he was equally clear that the company "will never stop thinking about that ideal day." Amidst these two positions, the production line continues to roll out successive new generations of anti-obesity drugs; meanwhile, the company maintains that sales in the United States have accelerated—rather than declined—following the entry of competitors into the market, attributing this to the product's quality and the preference shown for it by both physicians and patients.
Dostdar concluded with a clear strategic message: "Increasing the number of patients consistently using our products is the core of our future strategy." The company’s mission is to work with governments, payers, and individuals to ensure these medicines are made available as quickly and widely as possible both within the UAE and beyond.
No comments:
Post a Comment